Adam Martin-Schwarze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam Martin-Schwarze has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Anna J. Podolanczuk
Department of Medicine, Weill Cornell Medicine , New York, NY
1 shared publication - Anne Eb Sales
Sinclair School of Nursing, University of Missouri, Columbia, USA
1 shared publication - Ayodeji Adegunsoye
Department of Medicine, Section of Pulmonary & Critical Care, University of Chicago , Chicago, IL
1 shared publication Ben Trzaskoma
Genentech, Inc., South San Francisco, USA
1 shared publicationBianca Zaffarano
T. Yaw, B. Zaffarano Lloyd Veterinary Medical Center, College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011Present address of T. Yaw: N63 W23207 Main Street, Apt. 305, Sussex, Wisconsin 53089
1 shared publicationBingkai Wang
Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
1 shared publication
Latest Publications
- Open Access
- 23 September 2025
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 48, 101548
Rationale and protocol for a prospective clinical trial enrollment improvement hybrid study within a trial
- 23 September 2025
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 48, 101548
Open AccessRationale and protocol for a prospective clinical trial enrollment improvement hybrid study within a trial
- 15 July 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 208 (2) , 188-195
Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort
Rationale: Fatigue is a common and debilitating symptom for people living with interstitial lung disease (ILD). Studies on fatigue in ILD are limited, and little headway has been made toward developing interventions targeting the alleviation of fatigue. A barrier to progress is a lack of knowledge around the performance characteristics of a patient-reported outcome measure to assess fatigue in patients with ILD. Objectives: To assess the validity and reliability of the Fatigue Severity Scale (FSS) for measuring fatigue in a national cohort of patients with ILD. Methods: FSS scores and several anchors were measured in 1,881 patients from the Pulmonary Fibrosis Foundation Patient Registry. Anchors included the Short Form 6D Health Utility Index (SF-6D) score and a single vitality question from the SF-6D; the University of California, San Diego, Shortness of Breath Questionnaire; FVC; Dl CO; and 6-minute-walk distance. Internal consistency reliability, concurrent validity, and known-groups validity were assessed. Structural validity was assessed using confirmatory factor analysis. Measurements and Main Results: The FSS demonstrated high internal consistency (Cronbach’s α = 0.96). There were moderate to strong correlations between FSS score and patient-reported anchors (vitality question from the SF-6D [r = 0.55] and University of California, San Diego, Shortness of Breath Questionnaire total score [r = 0.70]) and weak correlations between FSS score and physiological measures (FVC [r = −0.24], percentage predicted Dl CO [r = −0.23], and 6-minute-walk distance [r = −0.29]). Higher mean FSS scores, indicating greater fatigue, were observed among patients using supplemental oxygen, those prescribed steroids, and those with lower percentage predicted FVC and percentage predicted Dl CO. The confirmatory factor analysis results suggest that the nine questions of the FSS reflect one dimension of fatigue. Conclusions: Fatigue is an important patient-centered outcome in ILD that is poorly correlated with physiological measures of disease severity, including lung function and walk distance. These findings further support the need for a reliable and valid measure of patient-reported fatigue in ILD. The FSS possesses acceptable performance characteristics for assessing fatigue and distinguishing different degrees of fatigue among patients with ILD.
- 15 July 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 208 (2) , 188-195
Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort
Rationale: Fatigue is a common and debilitating symptom for people living with interstitial lung disease (ILD). Studies on fatigue in ILD are limited, and little headway has been made toward developing interventions targeting the alleviation of fatigue. A barrier to progress is a lack of knowledge around the performance characteristics of a patient-reported outcome measure to assess fatigue in patients with ILD. Objectives: To assess the validity and reliability of the Fatigue Severity Scale (FSS) for measuring fatigue in a national cohort of patients with ILD. Methods: FSS scores and several anchors were measured in 1,881 patients from the Pulmonary Fibrosis Foundation Patient Registry. Anchors included the Short Form 6D Health Utility Index (SF-6D) score and a single vitality question from the SF-6D; the University of California, San Diego, Shortness of Breath Questionnaire; FVC; Dl CO; and 6-minute-walk distance. Internal consistency reliability, concurrent validity, and known-groups validity were assessed. Structural validity was assessed using confirmatory factor analysis. Measurements and Main Results: The FSS demonstrated high internal consistency (Cronbach’s α = 0.96). There were moderate to strong correlations between FSS score and patient-reported anchors (vitality question from the SF-6D [r = 0.55] and University of California, San Diego, Shortness of Breath Questionnaire total score [r = 0.70]) and weak correlations between FSS score and physiological measures (FVC [r = −0.24], percentage predicted Dl CO [r = −0.23], and 6-minute-walk distance [r = −0.29]). Higher mean FSS scores, indicating greater fatigue, were observed among patients using supplemental oxygen, those prescribed steroids, and those with lower percentage predicted FVC and percentage predicted Dl CO. The confirmatory factor analysis results suggest that the nine questions of the FSS reflect one dimension of fatigue. Conclusions: Fatigue is an important patient-centered outcome in ILD that is poorly correlated with physiological measures of disease severity, including lung function and walk distance. These findings further support the need for a reliable and valid measure of patient-reported fatigue in ILD. The FSS possesses acceptable performance characteristics for assessing fatigue and distinguishing different degrees of fatigue among patients with ILD.
- Open Access
- 8 December 2022
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (2) , 691-704
Real-World Clinical Outcomes Based on Body Mass Index and Annualized Weight Change in Patients with Idiopathic Pulmonary Fibrosis
Introduction Identification of clinical characteristics associated with prognosis for idiopathic pulmonary fibrosis (IPF) may help to guide management decisions. This analysis utilized data from the Pulmonary Fibrosis Foundation Patient Registry to examine the relationships between clinical outcomes and both body mass index (BMI) at study enrollment (hereafter referred to as baseline BMI) and annualized percent change in body weight in patients with IPF in a real-world setting. Methods The following outcomes over 24 months were stratified by baseline BMI and annualized percent change in body weight: all-cause mortality; annualized change in percent predicted forced vital capacity (%FVC), percent predicted diffusing capacity for carbon monoxide, and 6-min walk distance; all-cause and respiratory-related hospitalizations; and acute exacerbations. Results Overall, 600 patients with IPF were included (baseline BMI: < 25 kg/m2, n = 120; 25 to < 30 kg/m2, n = 242; ≥ 30 kg/m2, n = 238; annualized percent change in body weight: no loss, n = 95; > 0% to < 5% loss, n = 425; ≥ 5% loss, n = 80). Enrollment demographics and characteristics were generally similar across subgroups. There was no association between mortality and BMI. All-cause mortality was lower among patients who experienced no annualized weight loss versus those with ≥ 5% (OR [95% CI] 3.28 [1.15, 10.95]) or > 0 to < 5% weight loss (OR [95% CI] 2.83 [1.14, 8.62]) over 24 months. Patients with baseline BMI < 25 kg/m2 had a significantly greater estimated annualized decline in %FVC versus patients with baseline BMI ≥ 30 kg/m2 (difference [95% CI] 1.47 [0.01, 2.93]). No relationship was observed between %FVC and weight loss. Other clinical outcomes were generally similar across subgroups. Conclusions Some clinical outcomes may be worse in patients with IPF who have a low BMI (< 25 kg/m2) or who experience weight loss over 24 months, but the causation for these relationships is unknown. These results may help to inform management decisions for patients with IPF. ClinicalTrials.gov Identifier NCT02758808.
- 8 December 2022
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (2) , 691-704
Open AccessReal-World Clinical Outcomes Based on Body Mass Index and Annualized Weight Change in Patients with Idiopathic Pulmonary Fibrosis
Introduction Identification of clinical characteristics associated with prognosis for idiopathic pulmonary fibrosis (IPF) may help to guide management decisions. This analysis utilized data from the Pulmonary Fibrosis Foundation Patient Registry to examine the relationships between clinical outcomes and both body mass index (BMI) at study enrollment (hereafter referred to as baseline BMI) and annualized percent change in body weight in patients with IPF in a real-world setting. Methods The following outcomes over 24 months were stratified by baseline BMI and annualized percent change in body weight: all-cause mortality; annualized change in percent predicted forced vital capacity (%FVC), percent predicted diffusing capacity for carbon monoxide, and 6-min walk distance; all-cause and respiratory-related hospitalizations; and acute exacerbations. Results Overall, 600 patients with IPF were included (baseline BMI: < 25 kg/m2, n = 120; 25 to < 30 kg/m2, n = 242; ≥ 30 kg/m2, n = 238; annualized percent change in body weight: no loss, n = 95; > 0% to < 5% loss, n = 425; ≥ 5% loss, n = 80). Enrollment demographics and characteristics were generally similar across subgroups. There was no association between mortality and BMI. All-cause mortality was lower among patients who experienced no annualized weight loss versus those with ≥ 5% (OR [95% CI] 3.28 [1.15, 10.95]) or > 0 to < 5% weight loss (OR [95% CI] 2.83 [1.14, 8.62]) over 24 months. Patients with baseline BMI < 25 kg/m2 had a significantly greater estimated annualized decline in %FVC versus patients with baseline BMI ≥ 30 kg/m2 (difference [95% CI] 1.47 [0.01, 2.93]). No relationship was observed between %FVC and weight loss. Other clinical outcomes were generally similar across subgroups. Conclusions Some clinical outcomes may be worse in patients with IPF who have a low BMI (< 25 kg/m2) or who experience weight loss over 24 months, but the causation for these relationships is unknown. These results may help to inform management decisions for patients with IPF. ClinicalTrials.gov Identifier NCT02758808.
- Open Access
- 6 March 2021
- Published by Springer Nature in Journal of Agricultural, Biological and Environmental Statistics
- Vol. 26 (2) , 289-305
Joint Modeling of Distances and Times in Point-Count Surveys
Removal and distance modeling are two common methods to adjust counts for imperfect detection in point-count surveys. Several recent articles have formulated models to combine them into a distance-removal framework. We observe that these models fall into two groups building from different assumptions about the joint distribution of observed distances and first times to detection. One approach assumes the joint distribution results from a Poisson process (PP). The other assumes an independent joint (IJ) distribution with its joint density being the product of its marginal densities. We compose an IJ+PP model that more flexibly models the joint distribution and accommodates both existing approaches as special cases. The IJ+PP model matches the bias and coverage of the true model for data simulated from either PP or IJ models. In contrast, PP models underestimate abundance from IJ simulations, while IJ models overestimate abundance from PP simulations. We apply all three models to surveys of golden-crowned sparrows in Alaska. Only the IJ+PP model reasonably fits the joint distribution of observed distances and first times to detection. Model choice affects estimates of abundance and detection but has little impact on the magnitude of estimated covariate effects on availability and perceptibility.Supplementary materials accompanying this paper appear online.
- 6 March 2021
- Published by Springer Nature in Journal of Agricultural, Biological and Environmental Statistics
- Vol. 26 (2) , 289-305
Open AccessJoint Modeling of Distances and Times in Point-Count Surveys
Removal and distance modeling are two common methods to adjust counts for imperfect detection in point-count surveys. Several recent articles have formulated models to combine them into a distance-removal framework. We observe that these models fall into two groups building from different assumptions about the joint distribution of observed distances and first times to detection. One approach assumes the joint distribution results from a Poisson process (PP). The other assumes an independent joint (IJ) distribution with its joint density being the product of its marginal densities. We compose an IJ+PP model that more flexibly models the joint distribution and accommodates both existing approaches as special cases. The IJ+PP model matches the bias and coverage of the true model for data simulated from either PP or IJ models. In contrast, PP models underestimate abundance from IJ simulations, while IJ models overestimate abundance from PP simulations. We apply all three models to surveys of golden-crowned sparrows in Alaska. Only the IJ+PP model reasonably fits the joint distribution of observed distances and first times to detection. Model choice affects estimates of abundance and detection but has little impact on the magnitude of estimated covariate effects on availability and perceptibility.Supplementary materials accompanying this paper appear online.
- Open Access
- 1 August 2017
- Published by U.S. Fish and Wildlife Service in Journal of Fish and Wildlife Management
- Vol. 8 (2) , 465-473
Lead Poisoning in Bald Eagles Admitted to Wildlife Rehabilitation Facilities in Iowa, 2004–2014
Eleven years (2004–2014) of bald eagle Haliaeetus leucocephalus data from four independent, state and federally permitted wildlife rehabilitators in Iowa were assessed for the prevalence of elevated lead levels in blood or tissue samples. The relationship between blood lead concentrations and recorded information (age, season, radiographs, and clinical outcome) was investigated. Adult birds had higher blood lead concentrations than immature and juvenile birds. Highest blood lead levels were found during October–January. Bald eagles with positive radiographs for metallic opacities in the digestive tract had higher blood and tissue lead concentrations than those with negative results or those on which no radiograph was performed. Metallic opacities were identified through necropsy. Bald eagles with elevated levels of lead were associated with poor clinical outcomes, indicating that blood lead concentrations could be used as a predictor of clinical outcome.
- 1 August 2017
- Published by U.S. Fish and Wildlife Service in Journal of Fish and Wildlife Management
- Vol. 8 (2) , 465-473
Open AccessLead Poisoning in Bald Eagles Admitted to Wildlife Rehabilitation Facilities in Iowa, 2004–2014
Eleven years (2004–2014) of bald eagle Haliaeetus leucocephalus data from four independent, state and federally permitted wildlife rehabilitators in Iowa were assessed for the prevalence of elevated lead levels in blood or tissue samples. The relationship between blood lead concentrations and recorded information (age, season, radiographs, and clinical outcome) was investigated. Adult birds had higher blood lead concentrations than immature and juvenile birds. Highest blood lead levels were found during October–January. Bald eagles with positive radiographs for metallic opacities in the digestive tract had higher blood and tissue lead concentrations than those with negative results or those on which no radiograph was performed. Metallic opacities were identified through necropsy. Bald eagles with elevated levels of lead were associated with poor clinical outcomes, indicating that blood lead concentrations could be used as a predictor of clinical outcome.